A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Trastuzumab (Herceptin) in Patients With Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer

Trial Profile

A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Trastuzumab (Herceptin) in Patients With Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Oct 2013

At a glance

  • Drugs Vorinostat (Primary) ; Trastuzumab
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Oct 2013 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 08 Mar 2012 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
    • 08 Mar 2012 Status changed from suspended to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top